Yazar "Alandag, Celal" seçeneğine göre listele
Listeleniyor 1 - 3 / 3
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Effects of hormone receptor status on patient clinic and survival in HER2 positive breast cancer(Oxford Univ Press, 2024) Yilmaz, Mukaddes; Erdis, Eda; Ucar, Mahmut; Demir, Necla; Alandag, Celal; Yucel, BirsenBackground In the current study, the effect of hormone receptor (HR) status on clinical and survival in early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer was investigated. Methods Two hundred ninety-one patients with HER2- positive were examined in two categories as HR-positive and HR-negative. Results Of these, 197 (68%) were HR-positive and 94 (32%) were HR-negative with a mean follow-up period of 68 +/- 2.7 months. The groups were found to be similar in terms of age, menopausal status, comorbidity, pathologic type, stage, T stage, N stage, lymphovascular invasion, presence and percentage of intraductal component, multicentricity/focality and extracapsular invasion. Family history (P = 0.038), stage 2 tumor rate (P < 0.001), and perineural invasion (P = 0.005) were significantly higher in the HR-positive group. In the HR-negative group, mean Ki-67 value (P = 0.014), stage 3 tumor rate (P < 0.001), tumor necrosis (P = 0.004) and strong (3+) HER2 staining on immunohistochemical staining (P = 0.003) were higher. The incidence of relapse and metastasis, and the localization of metastasis were similar in both patient groups. The rate of locoregional relapse during the first 2 years was higher in the HR-negative patients than in the HR-positive patients (P = 0.023). Overall survival (OS) and disease-free survival (DFS) did not differ between the groups in univariate analysis. However, HR status was determined as an independent prognostic factor (HR: 2.11, 95% CI: 1.17-3.79; P = 0.012) for OS was not found to be significant for DFS in multivariate analysis. Conclusion Both clinicopathologic features and OS outcomes of HR-negative patients were worse than those of HR-positive patients.Öğe HER-2 SMASH(Springer, 2025) Alandag, Celal; Ozturk, Ayseguel; Yulak, Fatih; Inan, Zeynep Deniz Sahin; Karaca, Mustafa; Lacin, Burak Batuhan; Altun, AhmetPurposeHuman epidermal growth factor-2 (HER-2) targeted drugs are used in only HER-2 overexpressed cancers. However, only a small portion of these cancer types are HER-2 overexpressed. In this study, we aimed to upregulate HER-2 receptors in MCF-7 breast cancer and HT-29 colon cancer cell cultures, which these cells are not HER-2 upregulated in natural status.MethodsWe used a 10-day non-cytotoxic lapatinib dose to upregulate HER-2 receptors. HER-2 levels of these cell lines were tested with ELISA and immunofluorescence tests before and after 10 days of lapatinib administration. After upregulation of HER-2, we administered trastuzumab, and T-DM1 to these cell lines to observe whether there is an increase in anticancer activity. We used a cell viability test to show the cytotoxicity of trastuzumab and T-DM1. Also, we used ELISA and immunofluorescence for HER-2 pathway proteins to understand the mechanism of increased anti-cancer activity.ResultsWe showed that administration of lapatinib for 10 days leads to overexpression of HER-2 receptors on both MCF-7 and HT-29 cells. A significant increase in the cytotoxicity of trastuzumab or T-DM1 was observed after 10 days of lapatinib administration.ConclusionWe named this method the smash method, which is the volleyball term. In volleyball, the ball is raised while low and quickly hits the ground again, just like we do with the HER-2 receptor. The smash method can switch HER-2 negative or HER-2 low tumors into HER-2 overexpressed, iatrogenically. Thus, we can use her2-targeted therapies in all cancer patients instead of a small portion.Öğe HER-2 SMASH (vol 95, 10, 2025)(Springer, 2025) Alandag, Celal; Ozturk, Aysegul; Yulak, Fatih; Sahin Inan, Zeynep Deniz; Ozkaraca, Mustafa; Lacin, Burak Batuhan; Altun, Ahmet[No abstract available]
